We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QAN:ASXQantas Airways Limited Analysis

Data as of 2026-03-11 - not real-time

A$8.82

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Qantas shares are trading at AUD 8.82, well under the 20‑day SMA of 9.83, the 50‑day SMA of 10.13 and the 200‑day SMA of 10.52, indicating a bearish price trend. The RSI of 33 suggests the stock is approaching oversold territory, while the MACD histogram remains negative, reinforcing short‑term downside pressure. Yet the price sits above the calculated support level of 8.11 and well below the resistance of 11.09, leaving room for a bounce. Volatility is elevated at roughly 42% over the past month, but the beta of 0.49 points to muted sensitivity to broader market moves. On the valuation side, the market price is a fraction of the DCF‑derived fair value of AUD 28.9, implying a potential upside of nearly 39%, and the PE of 8.3 is dramatically lower than the industry average of 29.3, flagging the stock as deeply undervalued. The dividend yield of 4.5% with a modest 31% payout further enhances the appeal for income‑focused investors.
Recent material developments include a A$150 million on‑market share buyback programme and a marginal rise in statutory profit to AUD 925 million in H1 2026, underscoring management’s commitment to returning cash to shareholders. The continuation of a generous dividend, alongside the buyback, bolsters the case for a medium‑ to long‑term re‑rating despite the airline’s high debt load and negative free‑cash‑flow. Sector‑specific headwinds—fuel price exposure, regulatory scrutiny and cyclical demand—remain significant, but Qantas’s strong brand, loyal customer base and strategic initiatives provide a cushion that could support a gradual price recovery.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support but still above it
  • Bearish technical indicators (RSI, MACD)
  • High dividend yield providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Share buyback program signaling confidence
  • Significant valuation gap to DCF fair value
  • Sustainable dividend supporting cash returns

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Deep undervaluation relative to industry multiples
  • Strong brand and loyalty assets in a resilient market
  • Long‑term upside potential from DCF and strategic initiatives

Key Metrics & Analysis

Financial Health

Revenue Growth6.30%
Profit Margin6.53%
P/E Ratio8.3
ROE153.63%
ROA6.90%
Debt/Equity610.90
P/B Ratio9.9
Op. Cash FlowA$3.9B
Free Cash FlowA$-603500032
Industry P/E29.3

Technical Analysis

TrendBearish
RSI33.4
SupportA$8.11
ResistanceA$11.09
MA 20A$9.83
MA 50A$10.13
MA 200A$10.52
MACDBearish
VolumeIncreasing
Fear & Greed Index76.82

Valuation

Fair ValueA$28.90
Target PriceA$12.22
Upside/Downside38.57%
GradeUndervalued
TypeValue
Dividend Yield4.49%

Risk Assessment

Beta0.49
Volatility41.68%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.